FDA approves once-weekly semaglutide for weight loss The FDA approved once-weekly semaglutide injection for chronic weight management in adults with obesity or with overweight and at least one weight-related condition, according to an agency press release
Ann N Y Acad Sci 2002;967:379-388
It plays a role wherever purity is critical
Semaglutide and tirzepatide are both GLP-1 receptor agonists, medications that help regulate blood sugar levels and significantly reduce appetite, making it easier for individuals to lose weight
Sun Pharma is also introducing a patient support program , aimed at: This signals a shift toward holistic care models , not just drug sales
Semaglutide has been shown to lower appetite, control eating, and minimize food cravings, while also improving glycemic control